ArticleLeukemia research reports2026
Synergistic effects of luspatercept and cyclosporine A in lower-risk myelodysplastic syndrome with red cell aplasia: Two case insights.
Article in Leukemia research reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Luspatercept, an erythroid maturation agent, treats anemia in lower-risk myelodysplastic syndromes (MDS) by inhibiting SMAD2/3 signaling. However, its efficacy may be limited in immune-mediated erythroid suppression. We present two lower-risk MDS cases (per the Revised International Prognostic Scoring System) that developed red cell aplasia and poor response to luspatercept alone. Bone marrow showed near absence of erythroid precursors with multilineage dysplasia. Neither patient achieved hematologic improvement with luspatercept monotherapy. Cyclosporine A (Cy-A) was added, leading to hemoglobin improvement, transfusion independence, and marrow erythropoiesis recovery. These cases indicate red cell aplasia may reflect immune-mediated suppression, limiting luspatercept efficacy. The response to Cy-A highlights the potential role of immunosuppressive therapy. Combining luspatercept with Cy-A may offer a strategy for selected patients with lower-risk MDS and erythroid aplasia. Bone marrow reassessment should be considered in patients who fail to respond to luspatercept or who develop recurrent anemia after an initial response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.